Golden State Equity Partners’s Larimar Therapeutics LRMR Stock Holding History

Golden State Equity Partners’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,000	Closed	-$13.1K	–	683
2024 Q3	$13.1K	Buy	+2,000	New	+$16.1K	﹤0.01%	681
2023 Q4	$112K	Buy	24,715 +915	+4%	+$3.09K	0.03%	351
2023 Q3	$94K	Sell	23,800 -5,500	-19%	-$20.8K	0.03%	331
2023 Q2	$91.7K	Hold	29,300	–	–	0.03%	363
2023 Q1	$133K	Buy	+29,300	New	+$153K	0.07%	209
2022 Q1	$123K	Buy	30,415 +5,400	+22%	+$35.3K	0.06%	186
2021 Q4	$270K	Buy	+25,015	New	+$278K	0.14%	140

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Golden State Equity Partners's LRMR Position: Q4 2024 in Review

Golden State Equity Partners sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 2,000 shares — an estimated $13.1K sold.

Golden State Equity Partners first reported a position in LRMR in Q4 2021 and held it in 7 quarters. The position peaked at $270K in Q4 2021. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

Golden State Equity Partners reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
Golden State Equity Partners sold 2,000 Larimar Therapeutics shares in Q4 2024, an estimated $13.1K.
Golden State Equity Partners first reported a position in Larimar Therapeutics in Q4 2021 and held it in 7 quarters.
Golden State Equity Partners's Larimar Therapeutics position peaked at $270K in Q4 2021.
116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.